← All trials
NCT04882319
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- May 31, 2022
- First posted
- May 11, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Noven TherapeuticsLead sponsor
- Noven TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.